Category: Clinical Research/Diagn.
To Develop Japan’s First Blood Biomarker-Based Diagnostic Workflow for DementiaShimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
To Develop Japan’s First Blood Biomarker-Based Diagnostic Workflow for DementiaShimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research Read more
Making Nissui Pharmaceutical as a Wholly-Owned SubsidiaryExpanding the Clinical Testing Business Based on Synergies between Analytical and Measuring Instruments and Culture Media/Reagents
Making Nissui Pharmaceutical as a Wholly-Owned SubsidiaryExpanding the Clinical Testing Business Based on Synergies between Analytical and Measuring Instruments and Culture Media/Reagents Read more
Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare’s immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve therapy selection GE Healthcare’s Pharmaceutical Diagnostics business is an established global supplier of PET imaging tracers... Read more
GE Healthcare Introduces Omni Legend: A First-of-its-Kind All-Digital PET/CT System to Drive Efficiency, Enhance Diagnostics, and Deliver on Precision Medicine
Chicago, U.S. and Barcelona, Spain – October 16, 2022 – At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly introduces Omni Legend[i], the first system on its all-new, all-digital PET/CT platform. This cutting-edge system features a brand-new category of digital BGO (dBGO) detector material with a small crystal size that delivers... Read more
GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary endpoint, demonstrating higher diagnostic efficacy for [18F]flurpiridaz PET compared to SPECT Myocardial Perfusion Imaging (MPI) With a half-life roughly 12 times longer than currently approved cardiac PET radiotracers, if approved,... Read more